孕前糖尿病与妊娠:内分泌学会与欧洲内分泌学会联合临床实践指南
该指南由内分泌学会与欧洲内分泌学会联合制定,针对孕前糖尿病(含1型和2型糖尿病)患者孕前、孕期及产后的管理提出10个临床问题的推荐。指南采用GRADE方法评估证据 certainty 并形成推荐,纳入患者代表观点并考虑成本、可行性及健康公平性。推荐包括:每次生殖、糖尿病及初级保健就诊时询问妊娠意向(紧急护理/急诊就诊时如临床合适也建议询问);无妊娠意愿时使用避孕;2型糖尿病患者孕前停用GLP-1RA而非孕早期停用;已使用胰岛素的2型糖尿病孕妇不建议常规加用二甲双胍;孕期可选用限制碳水化合物饮食(<175 g/天)或常规饮食(>175 g/天);2型糖尿病孕妇可使用CGM或SMBG;使用CGM者不建议用单一24小时CGM目标<140 mg/dL替代标准孕期血糖目标;1型糖尿病孕妇建议使用混合闭环泵;基于风险评估早期分娩而非期待治疗;产后建议内分泌科随访管理糖尿病。所有推荐均为弱推荐(2),证据质量极低至低。
要点
- 对有生育可能的糖尿病患者,每次生殖、糖尿病及初级保健就诊时建议询问妊娠意向(2 | ⊕OOO);紧急护理/急诊就诊时如临床合适也建议询问。
- 无妊娠意愿的糖尿病女性建议使用避孕(2 | ⊕⊕OO),基于间接证据显示含避孕的孕前保健与首次产检HbA1c改善及先天畸形率降低相关。
- 2型糖尿病患者建议孕前停用GLP-1受体激动剂,而非在妊娠开始至孕早期结束之间停用(2 | ⊕OOO)。
- 已使用胰岛素的2型糖尿病孕妇,不建议常规加用二甲双胍(2 | ⊕OOO),因获益未超过增加小于胎龄儿及儿童期不良结局的潜在风险。
- 孕前糖尿病患者建议基于风险评估早期分娩而非期待治疗(2 | ⊕OOO),因超过38周妊娠期待治疗的风险可能超过获益。
适用人群与场景
- 有生育可能的糖尿病患者,包括1型糖尿病和2型糖尿病。
- 孕前糖尿病孕妇,包括孕期丢失或终止妊娠者。
诊断标准与关键阈值
- 标准孕期血糖目标:空腹<95 mg/dL(5.3 mmol/L),餐后1小时<140 mg/dL(7.8 mmol/L),餐后2小时<120 mg/dL(6.7 mmol/L)。
- 使用CGM的孕前糖尿病患者,不建议用单一24小时CGM目标<140 mg/dL(7.8 mmol/L)替代上述标准孕期血糖目标(2 | ⊕OOO)。
处置流程与药物剂量
- 对有生育可能的糖尿病患者,每次生殖、糖尿病及初级保健就诊时询问妊娠意向;紧急护理/急诊就诊时如临床合适也建议询问(2 | ⊕OOO)。
- 无妊娠意愿时建议使用避孕(2 | ⊕⊕OO)。
- 2型糖尿病患者建议孕前停用GLP-1受体激动剂,而非在妊娠开始至孕早期结束之间停用(2 | ⊕OOO)。
- 已使用胰岛素的2型糖尿病孕妇,不建议常规加用二甲双胍(2 | ⊕OOO)。
- 孕前糖尿病孕妇,建议限制碳水化合物饮食(<175 g/天)或常规饮食(>175 g/天)(2 | ⊕OOO)。
- 2型糖尿病孕妇,建议使用持续葡萄糖监测(CGM)或自我血糖监测(SMBG)(2 | ⊕OOO)。
- 1型糖尿病孕妇,建议使用混合闭环泵(根据CGM自动调整的泵),而非带CGM的胰岛素泵(无算法)或带CGM的每日多次胰岛素注射(2 | ⊕OOO)。
- 孕前糖尿病患者,建议基于风险评估早期分娩而非期待治疗(2 | ⊕OOO)。
研究设计与关键结果
- 指南制定小组由多学科临床专家及指南方法学和系统文献综述专家组成,确定并优先排序10个与糖尿病孕前、孕期及产后护理相关的临床问题。
- 优先纳入随机对照试验(RCT)评估不同干预(如孕前保健、营养、治疗选择、分娩)在糖尿病(包括1型糖尿病和2型糖尿病)患者生殖生命周期中的效果。
- 采用GRADE方法评估证据确定性并形成推荐,纳入2名患者代表观点,考虑患者价值观、成本与资源、可接受性与可行性及对健康公平的影响。
- 关于混合闭环泵的推荐基于RCT的Meta分析,显示血糖指标改善:目标范围内时间增加(均数差+3.81%;CI -4.24至11.86),低于范围时间减少(均数差-0.85%;CI -1.98至0.28)。
证据类型、等级与局限
- 证据类型:指南,采用GRADE方法评估证据确定性并形成推荐。
- 所有推荐均为弱推荐(2),证据确定性为极低至低(⊕OOO至⊕⊕OO)。
- 局限:支持这些推荐的数据确定性为极低至低,突出需要开展研究以提供高确定性证据;孕前保健的实施科学投入至关重要;需要RCT进一步确定孕期血糖目标并完善新兴技术;缺乏孕期最佳营养和肥胖管理的数据;需要更多关于孕前糖尿病患者分娩时机的研究。
对床旁实践的改变
- 对有生育可能的糖尿病女性,在生殖、糖尿病及初级保健就诊时询问妊娠意向,紧急护理/急诊就诊时如临床合适也询问(2 | ⊕OOO)。
- 无妊娠意愿时建议使用避孕(2 | ⊕⊕OO)。
- 2型糖尿病患者建议孕前停用GLP-1受体激动剂(2 | ⊕OOO)。
- 已使用胰岛素的2型糖尿病孕妇不建议常规加用二甲双胍(2 | ⊕OOO)。
- 孕前糖尿病孕妇可选用限制碳水化合物饮食(<175 g/天)或常规饮食(>175 g/天)(2 | ⊕OOO)。
- 2型糖尿病孕妇可使用CGM或SMBG(2 | ⊕OOO)。
- 使用CGM的孕前糖尿病患者,不建议用单一24小时CGM目标<140 mg/dL替代标准孕期血糖目标(2 | ⊕OOO)。
- 1型糖尿病孕妇建议使用混合闭环泵(2 | ⊕OOO);孕前糖尿病患者建议基于风险评估早期分娩而非期待治疗(2 | ⊕OOO);产后建议内分泌护理(2 | ⊕OOO)。
指南或共识出处
- Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.
- 制定机构:内分泌学会(Endocrine Society)与欧洲内分泌学会(European Society of Endocrinology)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Preexisting diabetes (PDM) increases the risk of maternal and perinatal mortality and morbidity. Reduction of maternal hyperglycemia prior to and during pregnancy can reduce these risks. Despite compelling evidence that preconception care (PCC), which includes achieving strict glycemic goals, reduces the risk of congenital malformations and other adverse pregnancy outcomes, only a minority of individuals receive PCC. Suboptimal pregnancy outcomes demonstrated in real-world data highlight the need to further optimize prenatal glycemia. New evolving technology shows promise in helping to achieve that goal. Dysglycemia is not the only driver of poor pregnancy outcomes in PDM. The increasing impact of obesity on pregnancy outcomes underscores the importance of optimal nutrition and management of insulin sensitizing medications during prenatal care for PDM.
OBJECTIVE: To provide recommendations for the care of individuals with PDM that lead to a reduction in maternal and neonatal adverse outcomes.
METHODS: The Guideline Development Panel (GDP) composed of a multidisciplinary panel of clinical experts, along with experts in guideline methodology and systematic literature review, identified and prioritized 10 clinically relevant questions related to the care of individuals with diabetes before, during and after pregnancy. The GDP prioritized randomized controlled trials (RCTs) evaluating the effects of different interventions (eg, PCC, nutrition, treatment options, delivery) during the reproductive life cycle of individuals with diabetes, including type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Systematic reviews queried electronic databases for publications related to these 10 clinical questions. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology was used to assess the certainty of evidence and develop recommendations. The approach incorporated perspectives from 2 patient representatives and considered patient values, costs and resources required, acceptability and feasibility, and impact on health equity of the proposed recommendations.
RESULTS: In individuals with diabetes mellitus who have the possibility of becoming pregnant, we suggest asking a screening question about pregnancy intention at every reproductive, diabetes, and primary care visit. Screening for pregnancy intent is also suggested at urgent care/emergency room visits when clinically appropriate (2 | ⊕OOO). This was suggested based on indirect evidence demonstrating a strong association between PCC and both reduced glycated hemoglobin (HbA1c) at the first prenatal visit and congenital malformations.In individuals with diabetes mellitus who have the possibility of becoming pregnant, we suggest use of contraception when pregnancy is not desired (2 | ⊕⊕OO). This was suggested based on indirect evidence in women with diabetes, where PCC-including contraception as a key component-showed a clinically significant association with improvements in first-trimester HbA1c and the rate of congenital malformations, together with indirect evidence from the general population regarding the reduction of unplanned pregnancies and pregnancy terminations with the use of contraception.In individuals with T2DM, we suggest discontinuation of glucagon-like peptide-1 receptor agonist (GLP-1RA) before conception rather than discontinuation between the start of pregnancy and the end of the first trimester (2 | ⊕OOO). This was suggested based on limited data on risk of exposure to GLP-1RA receptor agonists during pregnancy.In pregnant individuals with T2DM already on insulin, we suggest against routine addition of metformin (2 | ⊕OOO). This was suggested based on the GDP judgment that the benefit of adding metformin to insulin to achieve decrease in rates of large for gestational age infants did not outweigh the potential harm of increasing the risk of small for gestational age infants or adverse childhood outcomes related to changes in body composition.In individuals with PDM, we suggest either a carbohydrate-restricted diet (<175 g/day) or usual diet (>175 g/day) during pregnancy (2 | ⊕OOO). This was suggested based on the GDP judgment that the available evidence was limited and very indirect, resulting in significant uncertainty about the net benefits or harms. As such, the evidence was insufficient to support a recommendation either for or against a carbohydrate intake cutoff of 175 g/day.In pregnant individuals with T2DM, we suggest either the use of a continuous glucose monitor (CGM) or self-monitoring of blood glucose (SMBG) (2 | ⊕OOO). There is lack of direct evidence supporting superiority of CGM use over SMBG for T2DM during pregnancy. There is indirect evidence supporting improved glucometrics with the use of CGM for individuals with T2DM outside of pregnancy, substantial improvements in neonatal outcomes for individuals with T1DM using CGM during pregnancy and the potential for decreasing adverse pregnancy outcomes with improved glucometrics in individuals with T2DM.In individuals with PDM using a CGM, we suggest against the use of a single 24-hour CGM target <140 mg/dL (7.8 mmol/L) in place of standard-of-care pregnancy glucose targets of fasting <95 mg/dL (5.3 mmol/L), 1-hour postprandial <140 mg/dL (7.8 mmol/L), and 2-hour postprandial < 120 mg/dL (6.7 mmol/L) (2 | ⊕OOO). This was suggested based on indirect evidence that associated adverse pregnancy outcomes with a fasting glucose > 126 mg/dL (7 mmol/L).In individuals with T1DM who are pregnant, we suggest the use of a hybrid closed-loop pump (pump adjusting automatically based on CGM) rather than an insulin pump with CGM (without an algorithm) or multiple daily insulin injections with CGM (2 | ⊕OOO). This was suggested based on a meta-analysis of RCTs which demonstrated improvement in glucometrics with increased time in range (MD +3.81%; CI -4.24 to 11.86) and reduced time below range (MD -0.85%; CI -1.98 to 0.28) with the use of hybrid closed-loop pump technology.In individuals with PDM, we suggest early delivery based on risk assessment rather than expectant management (2 | ⊕OOO). This was suggested based on indirect evidence that risks may outweigh benefits of expectant management beyond 38 weeks gestation and that risk assessment criteria may be useful to inform ideal delivery timing.In individuals with PDM (including those with pregnancy loss or termination), we suggest postpartum endocrine care (diabetes management), in addition to usual obstetric care (2 | ⊕OOO). As the postpartum period frequently overlaps with preconception, this was suggested based on indirect evidence demonstrating a strong association between PCC and both reduced HbA1c at the first prenatal visit and congenital malformations.
CONCLUSION: The data supporting these recommendations were of very low to low certainty, highlighting the urgent need for research designed to provide high certainty evidence to support the care of individuals with diabetes before, during, and after pregnancy. Investment in implementation science for PCC is crucial to prevent significant mortality and morbidity for individuals with PDM and their children. RCTs to further define glycemic targets in pregnancy and refinement of emerging technology to achieve those targets can lead to significant reduction of harm and in the burden of diabetes care. Data on optimal nutrition and obesity management in pregnancy are lacking. More research on timing of delivery in women with PDM is also needed.
参考来源
- Wyckoff JA, Lapolla A, Asias-Dinh BD, et al. Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline. J Clin Endocrinol Metab. 2025. PMID: 40652453. doi:10.1210/clinem/dgaf288
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。